tranilast and Dermatitis--Atopic

Topics: Administration, Inhalation; Administration, Oral; Anti-Allergic Agents; Asthma; Contraindications; Cromolyn Sodium; Cystitis; Dermatitis, Atopic; Digestive System Diseases; Drug Eruptions; Hematologic Diseases; Humans; Kidney Diseases; ortho-Aminobenzoates

N(3',4'-dimethoxycinnamoyl) anthranilic acid (Tranilast) inhibits antibody-mediated hypersensitivity reactions, and is an effective drug for patients with bronchial asthma or allergic rhinitis. Interferon-gamma (IFN-gamma) production of ovalbumin (OA)-stimulated peripheral blood mononuclear cells (PBMCs) from hen's egg-sensitive patients with atopic dermatitis (AD) was significantly higher than those of healthy controls. Tranilast inhibited this IFN-gamma production. Moreover, interleukin-2 (IL-2) production of OA-stimulated PBMCs from hen's egg-sensitive patients with AD was also inhibited by Tranilast. Our results suggest that Tranilast can be used to the patients with food sensitive AD.

Topics: Anti-Allergic Agents; Cells, Cultured; Child, Preschool; Dermatitis, Atopic; Double-Blind Method; Food Hypersensitivity; Humans; Infant; Interferon-gamma; Interleukin-2; Lymphocytes; ortho-Aminobenzoates; Ovalbumin

Experimental studies have shown that N(3',4'-dimethoxycinnamoyl) anthranilic acid (Tranilast) inhibits reaginic antibody-mediated hypersensitivity reactions, and it has been demonstrated to be an effective drug for patients with bronchial asthma. On the other hand, from the nature of the cellular infiltrate seen in eczematous lesions, it appears that some form of cell-mediated immunity may be involved in addition to IgE-mediated immunity in the pathogenesis of atopic dermatitis (AD). Moreover, we have previously reported that the proliferative responses of peripheral blood mononuclear cells (PBMCs) to ovalbumin (OA) or bovine serum albumin (BSA) in children with AD who are sensitive to hen's egg or cow's milk were significantly higher than those of healthy children and hen's egg or cow's milk sensitive children with immediate symptoms. In this study, we have showed that the proliferative responses of PBMCs to OA were dose-dependently inhibited by Tranilast on patients with AD. The responding cells to OA were shown, through separation experiments, to be T cells, and the proliferative responses of T cells to OA were also dose-dependently inhibited by Tranilast. Moreover, the inhibition was thought to occur at the initial stage of the proliferative reactions. These results suggest that Tranilast can be clinically applied to patients with AD.

Topics: Antigens; Child; Child, Preschool; Dermatitis, Atopic; Food; Food Hypersensitivity; Histamine H1 Antagonists; Humans; In Vitro Techniques; Infant; Lymphocyte Activation; ortho-Aminobenzoates; Ovalbumin; Serum Albumin, Bovine

Patients with atopic dermatitis (AD) were treated with Tranilast, Interleukin-2 (IL-2) (production of T cells in vitro) and blood histamine values, before and after Tranilast therapy, were measured, and the following results were obtained: 1) Compared with healthy controls, the IL-2 producing ability of T cells in patients with AD was increased. 2) After Tranilast therapy, IL-2 production of T cells in AD decreased in quantity to the control level. 3) Skin lesion severities of AD were correlated with the quantity of IL-2 production of T cells. 4) Serum histamine levels were not significantly different between AD patients and healthy controls, before or after Tranilast therapy.

Topics: Adult; Child; Dermatitis, Atopic; Female; Histamine; Humans; Interleukin-2; Male; Middle Aged; ortho-Aminobenzoates; Skin; T-Lymphocytes

Topics: Administration, Oral; Adult; Aged; Dermatitis, Atopic; Desensitization, Immunologic; Humans; Middle Aged; ortho-Aminobenzoates